Ospedale Mater Salutis Di Legnago
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The cardiology department at Ospedale Mater Salutis Di Legnago is conducting studies that aim to improve outcomes for patients with atherosclerotic disease, coronary syndromes, and related vascular conditions. Researchers are evaluating new antiplatelet regimens, lipid‑lowering agents, and innovative biomarkers to guide therapy.
- Evaluation of long‑term antiplatelet strategies after percutaneous coronary intervention
- Investigation of Lp(a) reduction with pelacarsen in patients receiving background inclisiran
- Assessment of novel lipid‑lowering approaches to lower residual cardiovascular risk
These trials seek to determine whether newer treatment combinations can reduce major cardiac events while minimizing bleeding complications, offering safer and more effective options for individuals with established ASCVD.
Neoplasms
Oncology research at the site focuses on a broad spectrum of cancers, including ovarian, breast, lung, glioblastoma, and colon malignancies. The studies explore targeted therapies, immunotherapy combinations, and precision‑medicine strategies to enhance survival and quality of life for patients with advanced or high‑risk disease.
- Maintenance therapy with olaparib for BRCA‑wild type advanced ovarian cancer
- Adjuvant palbociclib versus chemotherapy in hormone‑receptor positive early breast cancer
- Combination immunotherapy for advanced non‑small cell lung cancer
- Biomarker‑driven intensification of adjuvant treatment using circulating tumor DNA in resected colon cancer
- Evaluation of re‑irradiation plus lomustine for recurrent glioblastoma
By testing these innovative approaches, the trials aim to improve response rates, extend progression‑free survival, and identify predictive markers that can personalize treatment for patients facing high‑grade and metastatic cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 43 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 43 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ospedale Mater Salutis Di Legnago
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT) | Merck Sharp & Dohme LLC | Phase II | Not Recruiting | Dec 2018 | Jun 2025 |
IMP list
lock Showing 1 of 43 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 2 | Unknown | 2019-06-14 | 2024-02-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.